BEGIN:VCALENDAR
PRODID:-//eluceo/ical//2.0/EN
VERSION:2.0
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:2d2fefc8b577dc8dc60fcca7596540fa
DTSTAMP:20260524T211913Z
SUMMARY:Thesis public defense - François PIERRARD
DESCRIPTION:Friday June 5\, 2026 – 4pm – Auditoire 51BFrançois PIERRAR
 D – IMCN and LDRI CMFADesign of Helical Peptides: From Cys–Cys Staplin
 g to New Cys–Lys MethodologiesConceptions de peptides hélicoïdaux: de 
 l'agrafage Cys–Cys vers de nouvelles méthodologies d'agrafage Cys–Lys
 Promotors: Prof. Raphaël Frédérick and Prof. Olivier RiantRelated publi
 cation:François Pierrard\, Yonghua Tan\, Prisca Zongo\, Vincent Stroobant
 \, Perrine Savoyen\, Khadija Wahni\, Joris Messens\, Olivier Riant\, and R
 aphaël Frédérick. A General One-Pot Strategy for Thiol-to-Amine Peptide
  Stapling via S-Alkylation and Reductive Amination\, submitted.Info: rapha
 el.frederick@uclouvain.beThe presentation will be in French.&nbsp\;
URL:https://www.uclouvain.be/en/calendar/ldri
DTSTART;TZID=Europe/Brussels:20260605T160000
DTEND;TZID=Europe/Brussels:20260605T173000
LOCATION:
END:VEVENT
BEGIN:VEVENT
UID:d8afe36d2a87a7eb0e130a1821ee5f5f
DTSTAMP:20260524T211913Z
SUMMARY:LDRI Seminar - Prof. Laure-Alix CLERBAUT
DESCRIPTION:Prof. Laure-Alix CLERBAUT&nbsp\;Prof. at Faculty of Bio-Enginee
 ring (AGRO)PI at Hepato-Gastroenterology (GAEN lab\, IREC) and at Biochemi
 stry of Nutrition and Environmental Toxicology (BNTE lab\, LIBST)For a far
 m to fork approach : introduction to the UCLouvain platforms (in LLN)follo
 wed by the seminarWhat happens when small meets smaller in the gut ?Relate
 d publications:•&nbsp\;&nbsp\;&nbsp\;&nbsp\;Gillard J\, Clerbaux LA\, Na
 chit M\, Sempoux C\, Staels B\, Bindels LB\, et al. Bile acids contribute 
 to the development of non-alcoholic steatohepatitis in mice. JHEP Rep. 202
 2\;4(1):100387•&nbsp\;&nbsp\;&nbsp\;&nbsp\;Gillard J\, Roumain M\, Pical
 ausa C\, Thibaut MM\, Clerbaux LA\, Tailleux A\, et al. A gut microbiota-i
 ndependent mechanism shapes the bile acid pool in mice with MASH. JHEP Rep
 . 2024\;6(11):101148Info: amandine.everard@uclouvain.be&nbsp\;
URL:https://www.uclouvain.be/en/calendar/ldri
DTSTART;TZID=Europe/Brussels:20260608T130000
DTEND;TZID=Europe/Brussels:20260608T140000
LOCATION:Avenue Emmanuel Mounier\, 51 1200 Bruxelles
END:VEVENT
BEGIN:VEVENT
UID:9166269b00bc61c7d2f1f2828208c0b2
DTSTAMP:20260524T211913Z
SUMMARY:LDRI Seminar - Dr Alexandra DEGRAEVE
DESCRIPTION:Dr Alexandra DEGRAEVE - MNUT - Postdoctoral Researcher in Pharm
 acomicrobiomicsContribution of the gut microbiome to pharmacokinetics to e
 xplain inter-patient variabilities: Tacrolimus and Methotrexate as Case St
 udiesRelated publications:•&nbsp\;&nbsp\;&nbsp\;&nbsp\;Degraeve\, A. L.\
 , Haufroid\, V.\, Loriot\, A.\, Gatto\, L.\, Andries\, V.\, Vereecke\, L.\
 , Elens L. &amp\; Bindels\, L. B. (2023). Gut microbiome modulates tacroli
 mus pharmacokinetics through the transcriptional regulation of ABCB1. Micr
 obiome\, 11(1)\, 138. doi : 10.1186/s40168-023-01578-y&nbsp\;•&nbsp\;&nb
 sp\;&nbsp\;&nbsp\;Degraeve\, A. L.\, Villa Soto\, V. S.\, Heath\, C. M.\, 
 Orellana\, D. A.\, Reilly\, E. R.\, Mukherjee\, M.\, ... &amp\; Nayak\, R.
  R. (2025). The gut microbiome shapes pharmacology and treatment outcomes 
 for a key anti-inflammatory therapy. bioRxiv\, 2025-06. https://www.biorxi
 v.org/content/10.1101/2025.06.26.661733v2.abstract&nbsp\;Info: laure.binde
 ls@uclouvain.be&nbsp\;
URL:https://www.uclouvain.be/en/calendar/ldri
DTSTART;TZID=Europe/Brussels:20260622T130000
DTEND;TZID=Europe/Brussels:20260622T140000
LOCATION:Avenue Emmanuel Mounier\, 51 1200 Bruxelles
END:VEVENT
BEGIN:VEVENT
UID:82249bb5a65ccb73ab93d92f8beda4f7
DTSTAMP:20260524T211913Z
SUMMARY:LDRI Seminar - Prof. Antonio MACCHIARULO
DESCRIPTION:Prof. Antonio MACCHIARULODipartimento di Scienze Farmaceutiche\
 , Università degli Studi di Perugia\, ItalyUntangling the Complexity of a
  Moonlight Enzyme: A Biophysical Deep Dive into IDO1Related publications:
 •&nbsp\;&nbsp\;&nbsp\;&nbsp\;Jeffery CJ. Moonlighting proteins. Trends B
 iochem. Sci. 1999. doi: 10.1016/s0968-0004(98)01335-8&nbsp\;•&nbsp\;&nbs
 p\;&nbsp\;&nbsp\;Pallotta MT\, et al. Indoleamine 2\,3-dioxygenase 1 (IDO1
 ): an up-to-date overview of an eclectic immunoregulatory enzyme. FEBS J. 
 2022. doi: 10.1111/febs.16086&nbsp\;•&nbsp\;&nbsp\;&nbsp\;&nbsp\;Coletti
  A. Ligand-induced conformations and dynamic allosteric motions of IDO1 af
 fecting the recruitment of a protein signaling partner. Commun Chem. 2025.
  doi: 10.1038/s42004-025-01648-2Info: raphael.frederick@uclouvain.be&nbsp\
 ;
URL:https://www.uclouvain.be/en/calendar/ldri
DTSTART;TZID=Europe/Brussels:20260623T110000
DTEND;TZID=Europe/Brussels:20260623T120000
LOCATION:Avenue Emmanuel Mounier\, 51 1200 Bruxelles
END:VEVENT
BEGIN:VEVENT
UID:f37b5dcc00925ffb7aabc49c4bf44ae6
DTSTAMP:20260524T211913Z
SUMMARY:LDRI Seminar - Prof. Erwin DREESEN
DESCRIPTION:Prof. Erwin DREESEN\, PharmD PhDAssistant professor and head of
  the Pharmacometrics Research Group in the Department of Pharmaceutical an
 d Pharmacological Sciences\, KU LeuvenModel-Informed Precision Dosing: Fro
 m Theory to PracticeRelated publications:•&nbsp\;&nbsp\;&nbsp\;&nbsp\;Ho
 ffert Y\, Wang Z\, Fumery M\, Nachury M\, Bazoge M\, Buisson A\, Dreesen E
 . A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous
  Switching of Infliximab in Patients With Inflammatory Bowel Diseases. Am 
 J Gastroenterol. 2026 Jan 1\;121(1):179-186. doi: 10.14309/ajg.00000000000
 03466.•&nbsp\;&nbsp\;&nbsp\;&nbsp\;Vuong ML\, Elkayal O\, Van Daele R\, 
 Alffenaar JC\, Stocker SL\, Roberts JA\, Debaveye Y\, Wauters J\, Mertens 
 B\, Boonstra JM\, Sandaradura I\, Marriott DJE\, Brüggemann RJ\, Schouten
  JA\, Bergner R\, Buijk S\, Spriet I\, Dreesen E. A fluconazole population
  pharmacokinetics study to improve target attainment in critically ill pat
 ients. Infection. 2025 Oct 14. doi: 10.1007/s15010-025-02663-0.&nbsp\;•&
 nbsp\;&nbsp\;&nbsp\;&nbsp\;Kantasiripitak W\, Outtier A\, Wicha SG\, Kense
 rt A\, Wang Z\, Sabino J\, Vermeire S\, Thomas D\, Ferrante M\, Dreesen E.
  Multi-model averaging improves the performance of model-guided infliximab
  dosing in patients with inflammatory bowel diseases. CPT Pharmacometrics 
 Syst Pharmacol. 2022\;11(8):1045-1059. doi: 10.1002/psp4.12813.Info: laure
 .elens@uclouvain.be&nbsp\;
URL:https://www.uclouvain.be/en/calendar/ldri
DTSTART;TZID=Europe/Brussels:20260629T130000
DTEND;TZID=Europe/Brussels:20260629T140000
LOCATION:Avenue Emmanuel Mounier\, 51 1200 Bruxelles
END:VEVENT
END:VCALENDAR